Earnings Summary

Arcutis Biotherapeutics Inc’s net profit fell -5.32% since last year same period to $-70.99Mn in the Q2 2023. On a quarterly growth basis, Arcutis Biotherapeutics Inc has generated 11.37% jump in its net profits since last 3-months.

Arcutis Biotherapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.38 - a 17.37% jump from last quarter’s estimates.

Arcutis Biotherapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.38.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Arcutis Biotherapeutics Inc’s return on assets (ROA) stands at -0.64.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Arcutis Biotherapeutics Inc’s return on equity (ROE) stands at -2.4.